scienceindustries basically supports efforts to initiate and implement modernization negotiations for the existing Switzerland-Japan free trade agreement, but not at any price. scienceindustries strongly opposes an amendment to the procedure for origin examination analogous to the EU-Japan Free Trade Agreement.
All our previous position papers are available in German
Position of scienceindustries on how to shape future trade relations with MERCOSUR: focus on improving market access and protection of intellectual property
For fundamental reasons, scienceindustries rejects the exclusion of products from negotiations for free trade agreements. Such exclusions not only contradict the spirit of free trade, but they are also diametrically opposed to the policy of comprehensive mutual market access for all trading partners.
- The member companies of scienceindustries are aware of their social responsibility and take this seriously - for decades, they have voluntarily got involved in a wide range of fields in CSR activities related to issues such as protecting the environment, promoting education and fighting corruption.
- The international community has created a multi-faceted set of CSR regulations incorporating guidelines and conduct recommendations for multinational companies. Government commitments beyond this are not a productive approach. Solo action on the part of Switzerland would be ineffective and would put an unnecessary strain on our country as a business location.
- Greater juridification of CSR and particularly the broadening of public liability for multinational companies - as provided by the Responsible Business Initiative - would be counter-productive. Rather, it is a question of increasing the responsibility of the economy itself.
Switzerland is a part of Europe from a cultural, geographical and economic point of view and has shared values. From an economic policy perspective, the bilateral approach is a story of success, which should be continued. The European Union is by far the most important trade partner for Chemistry Pharma Biotech, Switzerland's largest research and export industry.